Drug Trial Radar · NCT04270760
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
281
Actual
Start
Jul 28, 2020
Primary completion
Dec 27, 2021
Study completion Nov 8, 2022
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
Conditions
- Cardiovascular Disease
Interventions
OlpasiranDrug
Dose 1 Dose 2 Dose 3 Dose 4
PlaceboDrug
Dose 5
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36Time frame: Baseline and Week 36
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
Westside Medical Associates of Los Angeles
Beverly Hills, California
Excel Medical Clinical Trials
Boca Raton, Florida
Piedmont Healthcare
Atlanta, Georgia
University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins
Baltimore, Maryland
New York University
New York, New York
Mount Sinai Hospital
New York, New York
Columbia University Medical Center
New York, New York
Crossroads Clinical Research Inc
Mooresville, North Carolina
Cleveland Clinic
Cleveland, Ohio
Baylor College of Medicine
Houston, Texas
Protenium Clinical Research
Hurst, Texas
Dr Heart Pty Ltd
Woolloongabba, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Core Research Group Pty Ltd
Milton, Queensland, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
LMC Clinical Research Incorporated
Brampton, Ontario, Canada
LMC Clinical Research Incorporated Thornhill
Concord, Ontario, Canada
Ecogene-21
Chicoutimi, Quebec, Canada
Research Institute of McGill University Health Center - Glen Site
Montreal, Quebec, Canada
Clinique des Maladies Lipidiques de Quebec Incorporated
Québec, Quebec, Canada
Aarhus Universitetshospital
Aarhus N, Denmark
Herlev Gentofte Hospital
Herlev, Denmark
Regionshospitalet Viborg
Viborg, Denmark
Thjonustumidstod Rannsoknaverkefna
Kopavogur, Iceland
Asahi General Hospital
Asahi-shi, Chiba, Japan
The Jikei University Kashiwa Hospital
Kashiwa-shi, Chiba, Japan
Asahikawa City Hospital
Asahikawa-shi, Hokkaido, Japan
Kanazawa Medical University Hospital
Kahoku-gun, Ishikawa-ken, Japan
Saitama Medical University Hospital
Iruma-gun, Saitama, Japan
Academisch Medisch Centrum
Amsterdam, Netherlands
Rijnstate Ziekenhuis
Arnhem, Netherlands
Haga Ziekenhuis
The Hague, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
VieCuri Medisch Centrum
Venlo, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.